GRAIL and Premier’s PINC AI Partner to support patient access to Galleri multi-cancer early detection blood test

Jan. 12, 2022

GRAIL, LLC, a company whose mission is to detect cancer early when it can be cured, announced a collaboration with Premier, Inc.’s PINC AI, a platform that provides artificial intelligence-enabled clinical performance improvement technologies, to support patient access to Galleri, GRAIL’s multi-cancer early detection blood test.

Under the partnership, Premier’s PINC AI will augment its AI-enabled clinical decision support technology to alert clinicians to patients who present an elevated risk of cancer and may benefit from early detection with the Galleri test. The alert will be evidence-based, integrated in the workflow and is expected to be compatible with existing electronic medical record systems. Indianapolis-based Community Health Network is expected to be the first health system to pilot candidate alerts.

Dr. Joshua Ofman, president and chief medical officer at GRAIL said, “The partnership with Premier’s PINC AI, a trusted leader in healthcare technology, will support a key pillar of new early cancer detection technology – the identification of eligible patients through healthcare providers’ existing workflows.”

More than 600,000 people die from cancer each year in the U.S., according to the American Cancer Society. This is in large part because the majority of cancers are found in later stages when treatment options are limited. Recommended screening tests only cover five cancer types in the U.S.: breast, colon, cervical, prostate, and, in high-risk smokers, lung. More than 70 percent of cancer deaths are from cancers that lack recommended early detection screening.

In addition, studies have demonstrated that stage at diagnosis has the greatest impact on costs, with decreased costs for patients diagnosed early in the disease compared to those diagnosed at later stages.

“Galleri is a validated and transformational test that can detect more than 50 cancers with a single blood draw and predict the origin with a high degree of accuracy and a low rate of false positives,” said Patrick McGill, M.D., executive vice president and chief transformation officer at Community Health Network. “With this collaboration between PINC AI and GRAIL, our clinicians will be alerted when patients meet certain criteria for the ordering of a Galleri test. We believe this will make Community Health Network much more effective in our efforts to detect cancers early, when treatments are more effective, giving our patients the best chances of a successful outcome. Thanks to Community Health Network’s Foundation sponsorship and funding, we are proud to be the first health system taking advantage of this collaboration.”

Galleri is available in the U.S. by prescription only to complement existing single cancer screening tests.

Premier release

Photo 106117755 © Jakub Jirsak | Dreamstime.com
Photo 89319446 © Mohamed Ahmed Soliman | Dreamstime.com